Abstract: sKlotho， a soluble form of the anti-aging protein α-Klotho， exerts multifaceted biological effects. Chronic kidney disease （CKD）， marked by a deficiency in sKlotho， leads to the development of uremic cardiomyopathy （UC）. UC， characterized by left ventricular hypertrophy and myocardial fibrosis， is a detrimental condition and a leading cause of mortality in patients undergoing dialysis. Emerging research has highlighted the cardioprotective potential of sKlotho， particularly in modulating signaling pathways associated with myocardial hypertrophy， fibrosis， and cardiac electrophysiology. This article comprehensively reviews the protective roles and mechanisms of sKlotho in the context of uremic cardiomyopathy， offering insights into novel therapeutic avenues.

Key words: uremic cardiomyopathy, sKlotho, pathogenesis